An observational study in Hereditary Angioedema (HAE), sponsored by Takeda. Not yet recruiting at 7 sites in Egypt. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Takeda · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Angioedemas, Hereditary by Takeda — 3 open to participants now, 4 under way, none of them phase 3. Angioedemas, Hereditary · Takeda.
Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 9th largest by planned enrollment of the 21 observational ones that give a count, is the only one that started in 2027, is one of 21 observational ones, and was the 54th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →3 of the 58 studies in Angioedemas, Hereditary by Takeda are open now, in 3 countries. Recruiting first, the newest first:
Takeda · Sites in Korea, Republic of
Ages 12+
Takeda · Sites in Algeria
Ages 12+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 24 · Phase 4 1
First in 2003; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 43 observational studies indexed under Angioedemas, Hereditary.
Median enrollment 35 across the 36 interventional studies, 83 across the 21 observational. Of the 52 that completed or were terminated, 33 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 155 (87%) have results posted.
2 of the studies in Angioedemas, Hereditary by Takeda that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05469789TakedaA Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) | 2026-12-31 |
| NCT07293364TakedaA Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema | 2027-06-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 58 studies in Angioedemas, Hereditary by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hereditary angioedema (HAE) is a rare condition. It causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals. This swelling happens because of a temporary leak in blood vessels. HAE is classified based on the amount of a protein in the blood called C1 inhibitor (C1-INH): HAE with normal C1-INH levels and HAE with limited or insufficient C1-INH levels (C1-INH deficiency); HAE with C1-INH deficiency can be divided into Type1, with low levels of C1-INH, and Type 2, in which the protein is there, but does not work properly. This study will look at people with HAE Type1 or Type2.
The main aim of this study is to describe the diagnosis and management of people with HAE Type1 or HAE Type2 in Egypt. Other aims are to learn more about people with HAE Type1 or Type2, including, but not limited to, other conditions they may have, family history, impact of HAE on daily life, if treatment is stopped and the reasons.
During the study, information from already existing data in a participant's medical record will be reviewed and new data will be collected during routine visits of a participant to the study clinic.
Adult and pediatric participants with HAE-C1INH type1 or type2, treated within a routine clinical setting in Egypt.
Inclusion Criteria: Retrospective Phase:
Inclusion Criteria: Prospective Phase:
Exclusion Criteria: (For both retrospective and prospective phases):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants who were diagnosed with HAE-C1INH type1 or type2 from January 2015 to August 2025; retrospective clinical data will be extracted for 5 months exclusively from patients' medical charts, and no direct patient interaction will occur.
Other: No intervention
All participants with any newly diagnosed or admitted or follow-up HAE-C1INH type1 or type2; prospective clinical data will be actively collected over 12 months through routine visits and electronic data capture (EDC) entries.
Other: No intervention
This is a non-interventional study.
Age of Participants at Diagnosis (in years) of HAE-C1INH Type1 or Type2
Time frame: At Day 1
Percentage of Participants With HAE-C1INH Type1 or Type2
Time frame: At Day 1
Number and Type of First Symptom at Initial Manifestation
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With First Symptom at Initial Manifestation
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Duration of First Symptom at Initial Manifestation
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number and Type of Confirmed Diagnosis of HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Confirmed Diagnosis of HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Duration of Confirmed Diagnosis of HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants with Recorded Diagnostic Test Results for C1-INH Antigenic Level, Serum Complement Component 4 (C4) Level, and C1-INH Functional Level
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants Receiving On-demand (OD), Short-term prophylaxis (STP), and Multiple Long-Term Prophylaxis (LTP) Therapies
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants who Received Prescriptions for Therapeutic Management With HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Treatment Options Used for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Routes of Administration Used for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Dose Regimens Used for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants Switching Treatment for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Frequency of Treatment Changes for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Reason for Switching Treatment for the Therapeutic Management of Participants With HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Clinical Symptoms of HAE-C1INH Type1 or Type2 at Last Clinical Appointment
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Clinical Symptom Types of HAE-C1INH Type1 or Type2 at Last Clinical Appointment
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Duration of Clinical Symptoms of HAE-C1INH Type1 or Type2 at Last Clinical Appointment
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Known Triggers at Diagnosis
Triggers include stress, trauma, infection, contraception, menstruation, medication, food, burns, surgical procedures, and others.
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With History of Upper Airway Edema
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With History of Abdominal Surgery due to HAE Misdiagnosis
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With HAE-related Death
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Response to Standard Allergy Medications
Standard allergy medications (e.g. antihistamines, glucocorticoids, and epinephrine) that will be reported based on the symptom improvement, time to relief, reduction in symptom severity, and need for additional interventions.
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Presence of Comorbidities
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Average Number of HAE Attacks per Month
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Average Number of Attacks Requiring Acute Treatment per Month
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Average Number of Attacks Requiring Emergency Care or Hospitalization per Month
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Severity of HAE Attack per Each Attack
Number of participants with severity of HAE attack (mild, moderate, severe as reported or documented) per each attack.
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Time of HAE Attack(s) at Each Onset During Follow-Up Visits or Date of Last Recorded HAE Attack
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Duration of Symptoms for Each HAE Attack Onset During Subsequent Follow-Up Visits
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of HAE Attacks per Month
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants Categorized by HAE Attack Characteristics
HAE attack characteristics will include most common attack site(s) (e.g., abdominal, cutaneous, laryngeal), number of recurrent abdominal attacks, site of attack per each attack onset for each subsequent follow-up visit, and symptoms experienced per attack (e.g., pain, swelling, nausea).
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Prodromal Symptom
Prodromal symptoms before attacks such as general discomfort, tiredness, irritability, skin symptoms, rash, and paresthesia per each attack onset for each subsequent follow-up visit will be reported.
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With any Known Triggers Identified by the Participant as Related to the Onset of the Attack per Each Attack Onset for Each Subsequent Follow-up Visits
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With On-demand Treatment Medication for Each HAE Attack
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number and Type of Hospitalizations due to HAE Attacks
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Life-threatening Attacks
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants (Family Members) Diagnosed With HAE-C1INH Type1 or Type2
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Degree of Relation (Parent, Sibling, Child) to Diagnosed Family Members
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Presence of Laryngeal or Life-threatening Attacks in Relatives
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Rate of Testing and of Diagnosis Among Tested Family Members
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With History of HAE-related Deaths in the Family
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participant's Relatives who Underwent Clinical and/or Lab Assessment for HAE diagnosis
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Clinical Assessment for HAE Diagnosis With Symptoms Description for the Patient, their Descendants, or Relatives
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Laboratory Testing for the Participant, Their Descendants, or Relatives
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Follow-up Visits Routinely Performed (Average per Year) During the Retrospective and Prospective Phase
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants Who Missed Days at Work or School and Social Life due to HAE Attack
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Number of Participants With Treatment Discontinuation
Participants who discontinued the treatment due to reasons such as lack of efficacy, safety concerns, compliance issues, or others.
Time frame: Up to 5 months retrospectively, up to 12 months prospectively
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Start is estimated for Jan 2027; primary completion for Dec 2027, 10 months later.
Of 27 observational studies under Angioedemas, Hereditary, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 52. This study's planned 10 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Jan 2027, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.